

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)			Attorney Docket No. <b>056291-5283</b>			Application No. <b>10/578,663</b>	
			Applicants: HENNEQUIN <i>et al.</i>				
PTO Form 1449 December 4, 2008			Filing Date: January 17, 2007			Group Art Unit: <b>1624</b>	
<b>U.S. PATENT DOCUMENTS</b>							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	1.	US 2003/0186995	October 2, 2003	Kath et al.			
	2.	US 2004/0048880	March 11, 2004	Himmelsbach et al.			
<b>ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./</b>							
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document No.	Date	Country	XXX	XXX	Names
	3.	CA 2476008	October 9, 2003	Canada	Boehringer Ingelheim		
	4.	CA 2543649	May 12, 2005	Canada	"	"	
	5.	WO 01/21596	March 29, 2001	WIPO	Astrazeneca Ltd.		
	6.	WO 2004/046101	June 3, 2004	WIPO	Array Biopharma Inc.		
	7.	WO 2004/006846	January 22, 2004	WIPO	Ex Elixiris Inc.		
	8.	WO 2005/013998	February 17, 2005	WIPO	Astrazeneca Ltd.		
	9.	WO 2005/041973	May 12, 2005	WIPO	Boehringer Ingelheim Co.		
	10.	WO 2005/097134	October 20, 2005	WIPO	The Scripps Res. Inst.		
<b>ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./</b>							
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	11.	Ballard et al. "Developing a small molecule erbB2 inhibitor: challenges with optimising DMPK properties" Poster - Presented at DMDG Cambridge (February 6, 2008).					
	12.	Ballard et al. "Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorg Med Chem Lett. 17(22):6326-6329 (2007) .					
	13.	Barlaam et al. "A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(2):674-678 (2008) .					
	14.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 substitution as erbB2 kinase inhibitors: Structure-activity relationships and identification of a candidate drug" at AACR in 2007.					
	15.	Barlaam et al. "Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase" Bioorganic & Medicinal Chemistry Letters 18(6):1799-1803 (2008) .					
	16.	Barlaam et al. "Indazolylamino/Anilinoquinazolines Bearing a C-5 Substitution As erbB2 Kinase Inhibitors: Structure-Activity Relationships and Identification of a Candidate Drug" Poster number P044, presented at XXth International Symposium on Medicinal Chemistry (EFMC-ISMC 2008), Vienna, Austria, August 31 - September 4, 2008 .					
	17.	Cockerill et al. "Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2" Bioorganic & Medicinal Chemistry Letters 11(11):1401-1405 (2001) .					
	18.	Ducray et al. "Novel 3-alkoxy-1H-pyrazolo[3,4-d]pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 18(3):959-962 (2008) .					
	19.	Gaul et al. "Discovery and Biological Evaluation of Potent Dual ErbB-2/EGFR Tyrosine Kinase Inhibitors: 6-Thiazolylquinazolines" Bioorganic & Medicinal Chemistry Letters 13(4):637-640 (2003) .					
	20.	Harris et al. "Systematic variation of a key quinazoline core" Presented at the XXII European Colloquium on Heterocyclic Chemistry (XXII ECHC-2006) Bari, Italy, September 2-6, 2006 .					
	21.	Hennequin et al. "N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor" J Med Chem. 49(22):6465-6488 (2006) .					
Examiner <i>/Tamthom Truong/</i>			Date Considered	04/09/2009			
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)			Attorney Docket No. <b>056291-5283</b>		Application No. <b>10/578,663</b>		
			Applicants: HENNEQUIN <i>et al.</i>				
			PTO Form 1449 December 4, 2008		Filing Date: <b>January 17, 2007</b>		Group Art Unit: <b>1624</b>
<b>U.S. PATENT DOCUMENTS</b>							
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document No.	Date	Country	Class	Sub-Class	Translation
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	22.	Jani et al. "Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor" Cancer Research 67(20):9887-9893 (2007).					
	23.	Klutchko et al. "Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors" J Med Chem. 49(4):1475-1485 (2006) .					
	24.	Petrov et al. "Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series" Bioorg Med Chem Lett. 16(17):4686-4691 (2006) .					
<b>ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./</b>							
Examiner <i>/Tamthom Truong/</i>		Date Considered		04/09/2009			
<b>Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Examiner /Tamthom Truong/ Date Considered 04/09/2009

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.